Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is a clinical-stage biotechnology company with a promising pipeline of proprietary therapies focused on enhancing the function of regulatory T cells for the treatment of various diseases. With positive clinical data and partnerships in place, their venture into neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases has the potential to result in successful commercialization and revenue growth. While the company faces competition and regulatory challenges, their biomarker strategy and orphan drug designations provide some protection. As a development-stage company, valuation is complex and subject to forward assumptions.

Bears say

Coya Therapeutics is a clinical-stage biotechnology company with a negative outlook due to various reasons. First, the company has high operating expenses ($7.3 million in the second quarter of 2026) and limited revenue since it is still in the developmental stage. Additionally, the company is facing significant competition in the intensely competitive biotechnology and pharmaceutical industries. Furthermore, the company may need to raise additional capital in the future, which could dilute stockholders and be difficult to secure in the current financial environment.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.